Saroja Pharma Industries India (NSE:SAROJA) Piotroski F-Score: 5 (As of Aug. 31, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SAROJA Saroja Pharma Industries India Ltd NSE:SAROJA
15 GF Score
Price ₹40.95
! 4 Warning Signs
View Full Analysis

What is Saroja Pharma Industries India Piotroski F-Score?

Saroja Pharma Industries India NSE:SAROJA +3.15% 15 Piotroski F-Score is 5 as of Aug. 31, 2026, which is at its 10-year median of 5.00. GuruFocus rates NSE:SAROJA with a GF Score™ of 15/100. The stock has 4 warning signs investors should review. Among 984 Drug Manufacturers companies, Saroja Pharma Industries India ranks better than 61.08% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Saroja Pharma Industries India has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Saroja Pharma Industries India's Piotroski F-Score or its related term are showing as below:

NSE:SAROJA' s Piotroski F-Score Range Over the Past 10 Years
Min: 5   Med: 5   Max: 7
Current: 5

During the past 5 years, the highest Piotroski F-Score of Saroja Pharma Industries India was 7. The lowest was 5. And the median was 5.

Saroja Pharma Industries India  (NSE:SAROJA) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Saroja Pharma Industries India Piotroski F-Score Related Terms


Saroja Pharma Industries India Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Saroja Pharma Industries India's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Saroja Pharma Industries India Piotroski F-Score Chart

Saroja Pharma Industries India Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Piotroski F-Score
N/A N/A 5.00 7.00 5.00

Saroja Pharma Industries India Semi-Annual Data
Mar21 Mar22 Mar23 Mar24 Mar25
Piotroski F-Score N/A N/A 5.00 7.00 5.00

NSE:SAROJA vs ZTS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Saroja Pharma Industries India's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Saroja Pharma Industries India Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Saroja Pharma Industries India's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Saroja Pharma Industries India's Piotroski F-Score falls into.


NSE:SAROJA
15GF Score
Saroja Pharma Industries India Ltd NSE:SAROJA
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar25) TTM:Last Year (Mar24) TTM:
Net Income was ₹10.3 Mil.
Cash Flow from Operations was ₹11.5 Mil.
Revenue was ₹537.3 Mil.
Gross Profit was ₹51.5 Mil.
Average Total Assets from the begining of this year (Mar24)
to the end of this year (Mar25) was (265.624 + 395.527) / 2 = ₹330.5755 Mil.
Total Assets at the begining of this year (Mar24) was ₹265.6 Mil.
Long-Term Debt & Capital Lease Obligation was ₹13.8 Mil.
Total Current Assets was ₹272.2 Mil.
Total Current Liabilities was ₹224.9 Mil.
Net Income was ₹8.8 Mil.

Revenue was ₹406.7 Mil.
Gross Profit was ₹50.3 Mil.
Average Total Assets from the begining of last year (Mar23)
to the end of last year (Mar24) was (213.399 + 265.624) / 2 = ₹239.5115 Mil.
Total Assets at the begining of last year (Mar23) was ₹213.4 Mil.
Long-Term Debt & Capital Lease Obligation was ₹26.2 Mil.
Total Current Assets was ₹176.0 Mil.
Total Current Liabilities was ₹92.9 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Saroja Pharma Industries India's current Net Income (TTM) was 10.3. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Saroja Pharma Industries India's current Cash Flow from Operations (TTM) was 11.5. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar24)
=10.342/265.624
=0.03893473

ROA (Last Year)=Net Income/Total Assets (Mar23)
=8.783/213.399
=0.04115764

Saroja Pharma Industries India's return on assets of this year was 0.03893473. Saroja Pharma Industries India's return on assets of last year was 0.04115764. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Saroja Pharma Industries India's current Net Income (TTM) was 10.3. Saroja Pharma Industries India's current Cash Flow from Operations (TTM) was 11.5. ==> 11.5 > 10.3 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=13.808/330.5755
=0.04176958

Gearing (Last Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=26.206/239.5115
=0.10941437

Saroja Pharma Industries India's gearing of this year was 0.04176958. Saroja Pharma Industries India's gearing of last year was 0.10941437. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar25)=Total Current Assets/Total Current Liabilities
=272.16/224.895
=1.21016474

Current Ratio (Last Year: Mar24)=Total Current Assets/Total Current Liabilities
=175.976/92.919
=1.89386455

Saroja Pharma Industries India's current ratio of this year was 1.21016474. Saroja Pharma Industries India's current ratio of last year was 1.89386455. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Saroja Pharma Industries India's number of shares in issue this year was 4.02. Saroja Pharma Industries India's number of shares in issue last year was 3.53. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=51.497/537.268
=0.09584974

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=50.284/406.693
=0.12364117

Saroja Pharma Industries India's gross margin of this year was 0.09584974. Saroja Pharma Industries India's gross margin of last year was 0.12364117. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar24)
=537.268/265.624
=2.02266361

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar23)
=406.693/213.399
=1.90578681

Saroja Pharma Industries India's asset turnover of this year was 2.02266361. Saroja Pharma Industries India's asset turnover of last year was 1.90578681. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+0+0+0+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Saroja Pharma Industries India has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Saroja Pharma Industries India (NSE:SAROJA) has a Piotroski F-Score of 5 as of Aug. 31, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Saroja Pharma Industries India and its competitors. This is near median its historical median of 5.00. Over the past decade, Saroja Pharma Industries India's Piotroski F-Score has ranged from 5.00 to 7.00. According to the industry distribution chart, Saroja Pharma Industries India ranks #383 out of 984 companies in the Drug Manufacturers industry, placing it in the top 38.9%.
Is Saroja Pharma Industries India's Piotroski F-Score too high?
Saroja Pharma Industries India's current Piotroski F-Score of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 7.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Saroja Pharma Industries India's value of 5 is 0% at this industry median. Based on the distribution chart, Saroja Pharma Industries India ranks #383 out of 984 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Saroja Pharma Industries India has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Saroja Pharma Industries India's Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Saroja Pharma Industries India ranks #383 out of 984 companies for Piotroski F-Score. This puts Saroja Pharma Industries India in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Saroja Pharma Industries India's value of 5 is 0% at this benchmark. Historically, Saroja Pharma Industries India's own Piotroski F-Score has ranged from 5.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Saroja Pharma Industries India has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 984 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Saroja Pharma Industries India's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Saroja Pharma Industries India and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Saroja Pharma Industries India's current Piotroski F-Score is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Saroja Pharma Industries India stock overvalued right now?
Saroja Pharma Industries India (NSE:SAROJA) has a current Piotroski F-Score of 5. The current Piotroski F-Score is 5, which is near median its 10-year median of 5.00 and 0% at the Drug Manufacturers industry median of 5.00. Saroja Pharma Industries India's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Saroja Pharma Industries India (NSE:SAROJA), the current Piotroski F-Score is 5 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Saroja Pharma Industries India Business Description

Address Jata Shankar Dosa Marg, Shop No. 209, 2ND Floor, Ecstacy, City of Joy, Mulund west, Mumbai, MH, IND, 400080
Saroja Pharma Industries India Ltd is a company engaged in the pharmaceutical and healthcare sector. The company trades in pharmaceutical active pharmaceutical ingredients, pharma intermediates, chemicals, and solvents used for pharmaceutical products, including human and veterinary medicines. The company has only one reportable business segment, which is pharma chemicals, such as thionyl chloride and pharmaceutical intermediates. Geographically, it operates in India, Asia Pacific, Europe, and other regions, with the majority of its revenue generated from India.
15GF Score

Get the complete analysis for NSE:SAROJA

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹40.95
Price